Viridian Therapeutics target price raised to $54 from $50 by Leerink Partners
VRDN•Leerink Partners raised its target price for Viridian Therapeutics to $54 from $50.
Related News
Austin Gold nine-month net loss widens 87% to USD 1.99 million
AUST•
JPMorgan Chase announces dividend of R$ 0.6113062590 per unit
JPM•
Genesis Energy's Q3 net income falls on higher expenses
GEL•
Clear Secure target price raised to $50 from $45 by Wells Fargo
YOU•
Molson Coors cuts 2026 underlying EPS outlook to 16%-19% decline
TAP•